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Inhaled nitric oxide in premature infants: effect on tracheal
aspirate and plasma nitric oxide metabolites
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Objective: Inhaled nitric oxide (iNO) is a potential new therapy for
prevention of bronchopulmonary dysplasia and brain injury in premature
infants. This study examined dose-related effects of iNO on NO metabolites
as evidence of NO delivery.
Study Design: A subset of 102 premature infants in the NO CLD trial,
receiving 24 days of iNO (20 p.p.m. decreasing to 2 p.p.m.) or placebo, were
analyzed. Tracheal aspirate (TA) and plasma samples collected at enrollment
and at intervals during study gas were analyzed for NO metabolites.
Result: iNO treatment increased NO metabolites in TA at 20 and
10 p.p.m. (1.7- to 2.3-fold vs control) and in plasma at 20, 10, and
5 p.p.m. (1.6- to 2.3-fold). In post hoc analysis, treated infants with lower
metabolite levels at entry had an improved clinical outcome.
Conclusion: iNO causes dose-related increases in NO metabolites in the
circulation as well as lung fluid, as evidenced by TA analysis, showing NO
delivery to these compartments.
Journal of Perinatology (2010) 30, 275–280; doi:10.1038/jp.2009.155;
published online 8 October 2009
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Introduction
Improved survival among preterm infants over recent decades has
been associated with increased morbidities related to prematurity,
in particular bronchopulmonary dysplasia (BPD) or chronic lung
disease of prematurity.1 The pathophysiology of this disease
involves lung injury secondary to hyperoxia and mechanical
ventilation of an immature lung with associated inflammation
leading to increased airway resistance, impaired alveolarization,
and later interstitial fibrosis and enlarged airspaces.2,3
Under certain circumstances, inhaled nitric oxide (iNO) is a
promising new therapy for prevention of BPD.4–7 We earlier
reported clinical results for the NO CLD trial in which iNO was
administered at decreasing doses for 24 days, beginning between
7 and 21 days of life, to ventilated infants of 500 to 1250 g birth
weight. Treated infants had a significant reduction in the incidence
of BPD at 36 weeks postmenstrual age, less severe lung disease at
40 and 44 weeks, and better pulmonary outcome at 1 year of
age.6–8 In the three trials with prolonged iNO therapy, there was
no increase in the incidence of the common morbidities of
prematurity and evidence of neuroprotection in two trials.4,5
At present, there is no information regarding distribution and
metabolism of iNO in the premature infant. NO is rapidly oxidized
in vivo, and the concentrations of metabolites, primarily nitrite
and nitrate, serve as biomarkers for NO.9 The objective of this study
was to investigate the effect of iNO, as dosed in the NO CLD study,
on delivery of NO to the lung and absorption into the circulation.
We determined the relationship between levels of total NO
metabolites (NOx) in the tracheal aspirate (TA) and plasma at
different iNO doses, and investigated possible associations between
metabolite levels and infant outcome.
Methods
Studies were performed on a subset of infants enrolled in the
randomized, placebo-controlled trial (NO CLD) evaluating the
effect of iNO in preventing BPD.6 The study enrolled infants of 500
to 1250 g birth weight who were between 7 and 21 days of age and
required ventilatory support (mechanical ventilation or nasal
continuous positive airway pressure in infants 500 to 799 g).
Treated infants received decreasing concentrations of iNO
(INOmax, IKARIA, Clinton, NJ, USA) delivered using INOvent
(Datex-Ohmeda, Madison, WI, USA), beginning at 7 to 21 days of
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age according to the following schedule: 20 p.p.m. 3 days,
10 p.p.m. 7 days, 5 p.p.m. 7 days, 2 p.p.m. 7 days, for a
minimum duration of 24 days. Respiratory severity score was used
as an index of respiratory support and is calculated as mean airway
pressure fraction of inspired oxygen.
Samples of TA fluid and plasma were obtained at baseline
(before starting study gas) and within 24 h of each change of dose
of study gas (study days 1, 4, 11, and 18) or until the infant was
extubated. TA samples were obtained from 90 infants (47 placebo
treated and 43 iNO treated) and plasma samples were obtained
from 102 infants (50 placebo treated and 52 iNO treated) from four
centers (Children’s Hospital of Philadelphia, Hospital of the
University of Pennsylvania, Westchester Medical Center, and
Children’s Mercy Hospitals and Clinics in Kansas City, MO, USA).
Approval from the IRB at all participating institutions and
informed consent were obtained before patient enrollment and
sample collection.
TA samples were collected as described earlier10 using saline
lavage according to the schedule noted above. Aspirated samples
were placed in sterile tubes, centrifuged at 500 g for 10 min, and
the supernatants were stored at 70 1C. After thawing, samples
were centrifuged at 27 000 g for isolation of the large aggregate
surfactant fraction; results of the surfactant studies have been
reported.11 The remaining TA fluid was analyzed for NOx and
nitrite as well as analyses of inflammatory and oxidative stress
biomarkers that have been reported separately.12,13 Total NO
metabolites, consisting of nitrite, nitrate, S-nitroso, and N-nitroso
adducts as well as metal–NO complexes, were determined
using the Sievers Nitric Oxide Analyzer Model i280, which is
based on a gas-phase chemiluminescent reaction between NO
and ozone using vanadium chloride at 95 1C as the reducing
agent.14 Concentrations of nitrite were determined using potassium
iodide in acetic acid as the reducing agent at 37 1C. To account for
dilution of epithelial lining fluid by saline lavage during collection,
TA results were normalized to total protein as determined by
Bradford assay.15
Blood samples were obtained from the same subset of NO CLD
infants. Plasma was obtained by centrifugation, stored at 70 1C,
and analyzed for NOx using the Nitric Oxide Analyzer with
vanadium chloride reduction as described above. Plasma samples
were not stored in an adequate manner for separate analysis of
nitrite. Total NOx are reported as mM concentration.
Statistics were performed using STATA V9.2 (College Station, TX,
USA). We used the Mann–Whitney test for comparison of
nonparametric data such as normalized TA NOx and nitrite
comparisons and plasma NOx comparisons at each time point. For
continuous or normally distributed data such as severity score,
gestational age, and birth weight, the unpaired t-test was used. The
two-sample test for equality of proportions with continuity
correction was used when analyzing association between entry-level
NOx and outcome (by quartile).
Results
We obtained TA samples from 90 infants and plasma samples from
102 infants from a cohort of subjects enrolled in the NO CLD trial.6
There was no difference with respect to gestational age, birth
weight, age at entry, or entry severity score in the treatment or
control groups for infants with either TA samples or plasma
samples (Table 1). These demographics do not differ significantly
from those of the entire population of infants in the parent trial
(Table 1).
At study entry, before receiving study gas, there was no
difference in either TA or plasma NOx levels between control and
iNO-treated infants. Furthermore, there was no significant
correlation between gestational age, birth weight, age at entry, or
respiratory severity score at entry with NOx in plasma or TA at entry
(data not shown).
In control infants, there was no change in concentrations of TA
NOx or nitrite during the study period (Figures 1a and b,
respectively). iNO administration was associated with a 2.3-fold
increase in median TA NOx at 20 p.p.m. (51.7 vs 22.5 nmol mg
–1
protein, P¼ 0.0003) and a 1.7-fold increase at 10 p.p.m. (35.4 vs
20.4 nmol mg–1, P¼ 0.012). There were no significant differences
in NOx at either 5 p.p.m. (Figure 1) or 2 p.p.m. (data not shown).
The pattern was similar for nitrite concentrations, with significant
increases of 1.8-fold (6.3 vs 3.6 nmol mg–1, P¼ 0.22) at 20 p.p.m.
and 2.0-fold (7.8 vs 3.8 nmol mg–1, P¼ 0.017) at 10 p.p.m. for
iNO-treated infants. Nitrite as a percentage of total metabolites was
similar for both groups at all doses of study gas (mean was 14.2
and 14.4% for iNO and control infants, respectively).
NOx concentrations in plasma of placebo infants had no
apparent change during administration of study gas; the median
value for 270 samples from 50 infants collected over multiple time
points was 36.4mM. In iNO-treated infants, plasma NOx levels
(medians) were significantly increased compared with control
infants at 20 p.p.m. (95.9 vs 42.1mM, P<0.001), 10 p.p.m. (80.9 vs
35.5mM, P<0.001), and 5 p.p.m. (55.0 vs 34.6 mM, P¼ 0.0016),
but not at 2 p.p.m. (44.0 vs 38.7 mM, P¼ 0.37) (Figure 2a).
As infants administered control study gas had no apparent time-
dependent changes in plasma NOx, we examined the changes in
plasma NOx in iNO-treated infants as a function of NO gas doses.
Figure 2b shows that when these data are plotted as fold-increase
compared with the median control value, a clear dose–response
relationship is evident (Figure 2b). To measure the extent of
change in plasma NOx after iNO administration, we compared
values on days 1 and 3 (equivalent to 20 and recently switched
to 10 p.p.m. NO, respectively) to the individual infant’s pre-gas
value. Plasma NOx increased 2.9±0.2- and 3.6±0.3-fold
(mean±s.e., n¼ 37 and 28 on days 1 and 3, respectively). These
were significantly (P<0.05) greater than the changes seen in
infants receiving placebo gas (1.1±0.1- and 1.2±0.1-fold on
days 1 and 3).
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To elucidate the association between NO metabolite levels and
outcome, we first compared TA NOx, TA nitrite, or plasma NOx and
outcome in both the treatment and control group at all treatment
dose after therapy was initiated and found no significant
improvement or deterioration in outcome (data not shown).
However, in post hoc analysis, we tested for a possible relationship
between TA NOx levels at study entry, which reflects endogenous NO
levels, and the clinical outcome of survival without BPD at 36
weeks postmenstrual age (Table 2). Infants were divided into four
quartiles based on their NOx concentration in TA related to the
median of the entire group. In control infants, outcome was not
related to level of NOx at study entry. For treated infants, outcome
was better (87.5% survival without BPD) among infants with the
lowest quartile of NOx compared with the combined outcome for
the other three quartiles (34.6%, P¼ 0.027). The infants in the
lowest quartile of NOx did not differ from the remaining infants
from whom we received samples as well as those in the parent
trial6 with respect to gestational age (25.3 weeks), birth weight
(739 g), age at entry (16 days), or entry respiratory severity score
(3.5). For comparison, the infants in the highest quartile of NOx
had an average gestational age of 25.5 weeks, birth weight of 766 g,
age at entry of 17.6 days, and entry respiratory severity score
of 5.03. Regarding race, there were three Caucasian and five
African–American infants in the lowest quartile compared with
five Caucasian, two African American, and one Asian infant
in the highest quartile.
Discussion
The use of iNO in premature infants has only recently been
investigated in a series of randomized, controlled clinical trials.4–6,16
Most trial protocols for the use of iNO to prevent BPD have used
<14 days of treatment atp10 p.p.m. iNO. The NO CLD trial was
unique in its use of decreasing concentrations of iNO starting at
20 p.p.m. and in continuing treatment for 24 days by nasal
cannulae when an infant was extubated. This protocol provided the
opportunity to monitor NOx at different iNO doses over an extended
period. We report a dose-related effect of iNO on levels of NOx in
both TA and plasma, indicating effective delivery of NO to the
injured lung and systemic uptake of exogenous NO and/or its
metabolites. To our knowledge, this is the first description of
metabolites related to use of iNO in the infant. In addition, we
provide new information on endogenous NO levels, as reflected by
metabolite concentrations, in premature infants. At study entry
during the second or third postnatal week, before receiving study
gas, total metabolite levels were not associated with degree of
prematurity or severity of lung disease. However, a sub-population
of the study infants with lower metabolite levels seemed to have a
better clinical response to iNO, consistent with the concept of iNO
as replacement therapy for a developmental deficiency of
endogenous NO production.3,17
In the premature baboon model of BPD, iNO at 5 p.p.m. for
2 weeks beginning at birth improved respiratory function and lung
structure.3 The level of total NOx in TA fluid did not change,
consistent with our observations in the human infant at this
dose.18 Plasma NOx levels were increased Btwofold in treated
animals throughout the time of iNO administration, which is
similar to the findings at 5 to 10 p.p.m. iNO in this study of human
infants.
As NO cannot be directly measured in stored biological samples,
levels of nitrite and total NO oxidative metabolites were used as
surrogate markers for NO. Nitrite representedB14% of NOx in TA
fluid, indicating that nitrate and potentially other NO metabolites
constitute most of NO species present. Although it is clear from
both this study and the baboon model that iNO can lead to an
increase in plasma-borne NOx, it is uncertain whether NO and/or
its metabolites diffuse across the lung. Studies in mice and rabbits
showed that within 10 min after intratracheal instillation of nitrite,
Table 1 Demographic information for infants with metabolite measurements (compared with parent NO CLD trial)
Tracheal aspirate samples Plasma samples Parent trial (1)
iNO (n¼ 43) Placebo (n¼ 47) iNO (n¼ 52) Placebo (n¼ 50) iNO (n¼ 294) Placebo (n¼ 288)
Gestational age (weeks)a 25.5±1.4 25.6±1.6 25.6±1.4 25.6±1.6 26±1.5 26±1.5
Birth weight (g)a 757±168 734±148 746±157 737±146 766±161 759±155
Age at entry, days (interquartile range) 16 (14–21) 16 (14–21) 16 (13–20) 16 (12–20) 16 (12–19) 16 (13–19)
SSb at entry 4.0±2.2 4.0±2.2 3.7±2.2 3.7±1.9 3.5 3.5
Survival without BPD, n (%) 20 (46.5) 14 (29.8) 29 (55.7) 17 (34.0) 129 (43.9) 105 (36.5)
P-value P¼ 0.102 P¼ 0.027 P¼ 0.03
Abbreviation: iNO, inhaled nitric oxide.
aExpressed as mean±standard deviation.
bRespiratory severity score¼mean airway pressure fraction of inspired oxygen.
P>0.05 for all comparisons, except where indicated.
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the levels in lung and plasma were equal.19 Nitrite represents
a portion of the bioactive pool of NO metabolites and has been
shown to provide protection after ischemia–reperfusion injury
in a variety of tissues, including the brain, in animal studies.9
In this regard, it is noteworthy that Kinsella et al.5 showed on
head ultrasound an overall decrease in the combined outcome
of grade 3 or 4 intraventricular hemorrhage, periventricular
leukomalacia, and ventriculomegaly in their iNO-treated group.
Furthermore, Mestan et al.20 described an improvement in
neurodevelopmental outcome, specifically in the cognitive portion
of the Bayley Scale of Infant Development, in the iNO-treated
infants compared with control in the Schreiber trial,4 which
persisted after adjustment for the decrease in severe intraventricular
hemorrhage and periventricular leukomalacia. The observations
of elevated NOx support the possibility for extrapulmonary effects
of iNO in infants that may be independent of improved
pulmonary status.
There were no associations observed between TA or plasma NOx
concentrations at study entry and measures of prematurity or
severity of lung disease. Infant baboons delivered prematurely
(at the end of the second trimester) are deficient in endogenous NO
production, and NO synthase activity remains suppressed after
birth.17 Our observations suggest that endogenous NO production
in sick preterm human infants does not increase appreciably
Figure 1 Box and whisker plot of TA NOx (a) and TA nitrite (b) measurements
in iNO-treated infants and control infants by dose of study gas. The box represents
25th and 75th percentile with a median bar. The whiskers represent the 10th
and 90th percentiles and the heavy bar represents the mean of the samples.
Statistical significance was shown at 20 and 10 p.p.m. between the iNO-treated
and control infants for both NOx and nitrite. N¼ 34 and 36 at study entry, 37 and
42 at 20 p.p.m., 30 and 30 at 10 p.p.m., 19 and 23 at 5 p.p.m. for treated and
control infants, respectively. Only 11 samples for each group were available at
2 p.p.m. and median NOx values were 32.9 and 28.6 nmol mg
–1 protein and
nitrite values were 5.7 and 3.7 nmol mg–1 for treated and controls, respectively
(not shown).
Figure 2 (a) Box and whisker plot of plasma NOx in iNO-treated and control
infants by dose of study gas. NOx concentrations were significantly elevated
in treated infants compared with control at 20, 10, and 5 p.p.m. N¼ 48 and 47 at
study entry, 46 and 44 at 20 p.p.m., 42 and 45 at 10 p.p.m., 33 and 35 at
5 p.p.m., and 18 and 22 at 2 p.p.m. for treated and control infants, respectively.
(b) Plasma NOx concentrations in iNO-treated infants vs control infants by
increasing dose of study gas. The median NOx value for treated infants at
each dose of iNO as a percent of the median value of the relevant control infants
is presented. NOx values did not change with dose of study gas in control
infants. N values at each dose of iNO as noted in (a). Error bars represent
the proportional 25th and 75th percentile values.
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between 24 and 30 weeks, or, alternatively, that developmental
changes are not observed within the postnatal timeframe of this
study. The concentration of plasma NOx in control infants
(36.4 mM) is somewhat lower than the level reported for healthy
full-term infants on day 5 (55.2 mM), perhaps reflecting an effect of
gestational age.21
Infants with lower TA NOx levels at entry seemed to have a better
clinical response to iNO therapy (survival without BPD) than
infants with higher entry NOx, consistent with the concept that
insufficiency of endogenous NO contributes to BPD. An alternative
hypothesis is that the infants in the lowest quartile have a lesser
degree of inflammation or oxidative stress at study entry. To
support this hypothesis, we examined the 8-epi PGF 2a levels in
these infants and found them to be lower (86 ng mg–1 protein)
than what we have earlier reported in a larger group of iNO
responders,12 but there was wide variability in this measurement
(0.35 to 534 ng mg–1 protein). These results should be interpreted
with caution and need confirmation because of the relatively small
number of infants in each quartile of NOx concentration.
Conversely, we did not find an association with NOx levels and
adverse outcome at any dose in either the iNO-treated or control
infants in this study. Specific NO metabolites have been described
before in relation to BPD and response to therapy. Banks et al.
showed that a specific NO metabolite, 3-nitrotyrosine, is elevated in
plasma in the first month of life in infants who develop BPD.
Furthermore, increased levels of 3-nitrotyrosine after the first
month of life correlated with the fraction of inspired oxygen the
infant was receiving.22 Lorch et al. described the plasma levels of
3-nitrotyrosine in infants with BPD who were receiving iNO. A
significant decrease within the first 72 h after starting therapy was
observed in those infants who were weaned off mechanical
ventilation compared with those who remained on mechanical
ventilation at discharge or who expired.23 These data suggest that
markers of nitrative and oxidative stress are associated with both
BPD and response to therapy. We have previously reported from
data in the NO CLD trial that 3-nitrotyrosine did not change in
infants with and without BPD, whether they were receiving iNO or
placebo.13 This discrepancy may be explained by differences in
study population, severity of illness, progression of clinical course,
when samples were taken, or differences in assay techniques.
However, given that 3-nitrotyrosine is a small component of total
NOx metabolites, it is not surprising that we did not see changes in
this study.
There are several limitations to this study. First, TA samples
could not be obtained after infants were extubated, which reduced
the number of samples available at 5 and 2 p.p.m. and accordingly
reduced the power of our study at these points. In general,
variability in the TA data was greater than in plasma values, which
reflects in part the necessity to use an imperfect denominator (total
protein) to correct for dilution of epithelial lining fluid by the
lavage saline. Second, infants from whom samples were received
were from a subset of NO CLD trial sites enrolling patients.
Although their demographics were the same as infants in the
parent trial, and, therefore, representative of the entire cohort, this
remains a limitation. Third, although infants in this study had
similar nutritional management strategies, there was no specific
control over or measurement of nitrate intake, which may
influence the measurement of NOx within plasma. Lastly, as NO
cannot be directly measured within these samples, one must rely
on measurements of its most abundant metabolites as markers of
NO content.
In conclusion, we have shown that iNO therapy for premature
infants results in dose-related increases in NOx in both lung fluid
and the circulation. These findings indicate the efficiency and
quantitative nature of NO delivery to infants with lung disease and
raise the possibility of increased delivery of NO to other tissues with
iNO therapy. As iNO treatment is not associated with increased
incidence of co-morbidities of prematurity, and may offer
neuroprotection, uptake of NO and metabolites into the circulation
may represent an additional benefit of iNO for the at-risk
premature infant.
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